Your browser doesn't support javascript.
loading
ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.
Bloch, Evan M; Patel, Eshan U; Marshall, Christi; Littlefield, Kirsten; Goel, Ruchika; Grossman, Brenda J; Winters, Jeffrey L; Shrestha, Ruchee; Burgess, Imani; Laeyendecker, Oliver; Shoham, Shmuel; Sullivan, David; Gehrie, Eric A; Redd, Andrew D; Quinn, Thomas C; Casadevall, Arturo; Pekosz, Andrew; Tobian, Aaron A R.
Afiliación
  • Bloch EM; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Patel EU; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Marshall C; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Littlefield K; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Goel R; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Grossman BJ; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Winters JL; Mississippi Valley Regional Blood Center, Springfield, IL, USA.
  • Shrestha R; Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Burgess I; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Laeyendecker O; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Shoham S; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Sullivan D; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
  • Gehrie EA; Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Redd AD; Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Quinn TC; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Casadevall A; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
  • Pekosz A; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
  • Tobian AAR; Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vox Sang ; 116(7): 766-773, 2021 Aug.
Article en En | MEDLINE | ID: mdl-33493365
BACKGROUND AND OBJECTIVES: ABO blood group may affect risk of SARS-CoV-2 infection and/or severity of COVID-19. We sought to determine whether IgG, IgA and neutralizing antibody (nAb) to SARS-CoV-2 vary by ABO blood group. MATERIALS AND METHODS: Among eligible convalescent plasma donors, ABO blood group was determined via agglutination of reagent A1 and B cells, IgA and IgG were quantified using the Euroimmun anti-SARS-CoV-2 ELISA, and nAb titres were quantified using a microneutralization assay. Differences in titre distribution were examined by ABO blood group using non-parametric Kruskal-Wallis tests. Adjusted prevalence ratios (aPR) of high nAb titre (≥1:160) were estimated by blood group using multivariable modified Poisson regression models that adjusted for age, sex, hospitalization status and time since SARS-CoV-2 diagnosis. RESULTS: Of the 202 potential donors, 65 (32%) were blood group A, 39 (19%) were group B, 13 (6%) were group AB, and 85 (42%) were group O. Distribution of nAb titres significantly differed by ABO blood group, whereas there were no significant differences in anti-spike IgA or anti-spike IgG titres by ABO blood group. There were significantly more individuals with high nAb titre (≥1:160) among those with blood group B, compared with group O (aPR = 1·9 [95%CI = 1·1-3·3], P = 0·029). Fewer individuals had a high nAb titre among those with blood group A, compared with group B (aPR = 0·6 [95%CI = 0·4-1·0], P = 0·053). CONCLUSION: Eligible CCP donors with blood group B may have relatively higher neutralizing antibody titres. Additional studies evaluating ABO blood groups and antibody titres that incorporate COVID-19 severity are needed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistema del Grupo Sanguíneo ABO / COVID-19 Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Vox Sang Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistema del Grupo Sanguíneo ABO / COVID-19 Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Vox Sang Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido